OrthoPediatrics Corp. (KIDS)
KIDS Stock Gains From Its New Enabling Technologies Division Launch
OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.
Wall Street Analysts Predict a 31.2% Upside in OrthoPediatrics (KIDS): Here's What You Should Know
The consensus price target hints at a 31.2% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OrthoPediatrics Corp. (KIDS) Q2 2024 Earnings Call Transcript
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Rick Wise - Stifel Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Mike Matson - Needham Dave Turkaly - Citizens JMP Ravi Misra - Truist Operator Good morning, and thank you for standing-by. Welcome to the Second Quarter 2024 OrthoPediatrics Earnings Conference Call.
OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.19 per share a year ago.
OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?
OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
